Retatrutide is an investigational triple agonist acting on GLP-1, GIP, and glucagon receptors, not yet approved by the MHRA or EMA for use in the UK
If you don't exercise, you're missing that essential dose
These drugs are fairly new, and the long-term effects, particularly when used by younger people who are potentially still developing and growing, haven't been studied
At the signaling pathway level, ROS down-regulate PR signaling through NF-B/MAPK signaling pathway, and then inhibit the transcription of PRL and IGFBP-1 (77, 78)
Remember that even the most sophisticated approved oral peptide, semaglutide, achieves only about 1% or less absolute bioavailability and demands strict administration conditions to work at all
Retatrutide and Tirzepatide: Differences That Matter Retatrutide is often compared with tirzepatide because both affect incretin pathways